Manager × security

RAFFLES ASSOCIATES LP LCTX holdings history

Who else holds this security? →

LINEAGE CELL THERAPEUTICS IN · CUSIP 53566P109 · CIK 1169581

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, RAFFLES ASSOCIATES LP reported 5.20M LCTX (shares), valued at $6.81M, or 5.80% of its reported non-derivative portfolio. Filed 2026-08-17.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
5.80%
Shares
5.20M
5,197,788
Reported value
$6.81M
USD

Shares decreased 3.08%; reported value decreased 19.64%, and weight changed -1.55 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20265.80%5,197,788SEC filing ↗Filed Aug 17, 2026Amended
Q1 20267.35%5,362,788SEC filing ↗Filed May 15, 2026
Q4 20256.72%5,362,788SEC filing ↗Filed Feb 17, 2026
Q3 20258.48%5,387,788SEC filing ↗Filed Nov 14, 2025
Q2 20255.10%5,392,088SEC filing ↗Filed Aug 15, 2025
Q1 20253.10%5,642,088SEC filing ↗Filed May 15, 2025
Q4 20242.97%5,492,088SEC filing ↗Filed Feb 14, 2025
Q3 20244.19%4,507,781SEC filing ↗Filed Nov 14, 2024
Q2 20244.90%4,357,781SEC filing ↗Filed Aug 14, 2024
Q1 20245.51%3,209,981SEC filing ↗Filed May 15, 2024
Q4 20232.94%2,131,621SEC filing ↗Filed Feb 14, 2024
Q3 20232.48%1,587,739SEC filing ↗Filed Nov 15, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20232.48%1,587,739$1.87MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 15, 2023
Q4 20232.94%2,131,621$2.32MShares increased 34.26%; reported value increased 24.02%, and weight changed +0.46 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2024
Q1 20245.51%3,209,981$4.75MShares increased 50.59%; reported value increased 104.47%, and weight changed +2.57 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 20244.90%4,357,781$4.35MShares increased 35.76%; reported value decreased 8.52%, and weight changed -0.61 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 20244.19%4,507,781$4.08MShares increased 3.44%; reported value decreased 6.10%, and weight changed -0.71 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20242.97%5,492,088$2.76MShares increased 21.84%; reported value decreased 32.37%, and weight changed -1.22 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20253.10%5,642,088$2.55MShares increased 2.73%; reported value decreased 7.67%, and weight changed +0.13 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 20255.10%5,392,088$4.89MShares decreased 4.43%; reported value increased 92.03%, and weight changed +2.00 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 15, 2025
Q3 20258.48%5,387,788$9.11MShares decreased 0.08%; reported value increased 86.10%, and weight changed +3.38 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2025
Q4 20256.72%5,362,788$8.96MShares decreased 0.46%; reported value decreased 1.64%, and weight changed -1.76 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 20267.35%5,362,788$8.47MShares unchanged; reported value decreased 5.39%, and weight changed +0.63 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 20265.80%5,197,788$6.81MShares decreased 3.08%; reported value decreased 19.64%, and weight changed -1.55 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 17, 2026
RAFFLES ASSOCIATES LP · LINEAGE CELL THERAPEUTICS IN

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1169581","quarter":"2026Q2","cusip":"53566P109"}

get_institutional_manager_history
{"cik":"1169581","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.